Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE

(GSK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 01:49am EDT
The logo of Stada Arzneimittel AG is pictured at their headquarters in Bad Vilbel near Frankfurt

FRANKFURT (Reuters) - German generic drugmaker Stada will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development deals with partners, the company's chief executive told Reuters.

"We are very selective but we take a look at everything," said CEO Peter Goldschmidt, who took the helm a year ago.

The company, majority owned by buyout firms Bain and Cinven since 2017, sells consumer healthcare products such as painkillers, sunscreen lotions as well as biosimilar and generic drugs, which are cheaper copies of established pharmaceuticals that have lost patent protection.

The new owners at the time were widely expected to pursue other deals to combine Stada with a peer in consumer healthcare or generic drug markets, but the German company has so far stayed away from larger deals.

"We have very good organic growth. Our first goal is to have good partnerships," he added, referring to collaboration deals with developers and producers.

Stada is expected to be among the suitors for a portfolio of drugs for sale in western Europe that Japan's Takeda Pharmaceutical is divesting to trim its debt following the $59 billion (£49 billion) purchase of Shire, sources close to the matter told Reuters last month.

Goldschmidt declined to comment on the transaction, saying there was no shortage of alternative deals to pursue for Stada.

"There are five or six comparable opportunities, that are currently in the market or will come to the market," the CEO said.

The generic drugmaker on Wednesday reported an increase in adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of 13% to 295 million euros (£273 million) during the fist half.

Sales during the first six months of the year gained 11% to 1.26 billion euros, helped by growth in generic prescription drugs and consumer health products.

Stada agreed in June to buy six consumer brands, including itch relief cream Eurax and Tixylix cough liquids, from British drugmaker GlaxoSmithKline for an undisclosed price to bolster its presence in Europe.

The Hesse-based company is focusing on Europe and has shied away from doing business in the United States, where generic drug companies have come under price pressure.

(Reporting by Ludwig Burger and Patricia Weiss,; Editing by Tassilo Hummel and Sherry Jacob-Phillips)

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE 0.91% 1691.2 Delayed Quote.13.41%
PFIZER -2.11% 34.34 Delayed Quote.-19.63%
STADA ARZNEIMITTEL 0.00%End-of-day quote.-8.87%
TAKEDA PHARMACEUTICAL CO LTD -0.08% 3548 End-of-day quote.-1.99%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
08/23GSK builds oncology pipeline as drug shown to help myeloma patients
RE
08/23GLAXOSMITHKLINE : GSK - positive results from pivotal DREAMM-2 study
PU
08/23GLAXOSMITHKLINE : Achieves Positive Results Blood Cancer Treatment Study
DJ
08/22GSK submits first regulatory application for daprodustat in Japan for patient..
AQ
08/22GSK's long acting HIV injection gets boost from study
RE
08/22GLAXOSMITHKLINE : ViiV Healthcare Reports Positive HIV Trial Results
DJ
08/22GLAXOSMITHKLINE : ViiV results positive for every 2 month injection
PU
08/21LONDON STOCK EXCHANGE : Oil majors, exporters boost FTSE 100; Fed minutes eyed
RE
08/21GSK SUBMITS REGULATORY FILE IN JAPAN : Daprodustat
PU
08/20Board of directors meeting of GlaxoSmithKline Consumer Healthcare Pakistan Li..
AQ
More news
Financials (GBP)
Sales 2019 32 481 M
EBIT 2019 8 745 M
Net income 2019 4 773 M
Debt 2019 22 986 M
Yield 2019 4,73%
P/E ratio 2019 17,7x
P/E ratio 2020 17,3x
EV / Sales2019 3,28x
EV / Sales2020 3,06x
Capitalization 83 688 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Average target price 1 704,90  GBp
Last Close Price 1 691,20  GBp
Spread / Highest target 17,4%
Spread / Average Target 0,81%
Spread / Lowest Target -17,2%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE13.41%102 699
JOHNSON & JOHNSON-1.02%337 101
ROCHE HOLDING LTD.11.71%237 836
MERCK AND COMPANY11.16%217 478
NOVARTIS18.13%204 739
PFIZER-19.63%189 936